Business & Finance
Juniper Pharmaceuticals Extends Crinone Supply Agreement with Merck KGaA, Darmstadt, Germany through 2024
12 January 2018 - - Boston, Massachusetts-based women's health therapeutics company Juniper Pharmaceuticals (NASDAQ: JNP) has extended its supply agreement for Crinone (progesterone gel) with an affiliate of Merck KGaA, Darmstadt, Germany, the company said.
The amended agreement extends the supply term an additional 4.5 years and at least through to December 31, 2024. The current term was due to expire in May 2020.
Merck KGaA, Darmstadt, Germany has marketing rights worldwide except the US, where Crinone is marketed by Allergan plc.
Under the terms of the amended license and supply agreement, Juniper will remain the supplier of Crinone to Merck KGaA, Darmstadt, Germany and will continue to sell Crinone to Merck KGaA, Darmstadt, Germany for the more than 90 countries outside of the US where Crinone is sold.
The agreement also sets from 1 July 2020, a volume tiered, fixed price per unit with minimum annual volume guarantees. In addition, Juniper has committed to increase the capacity of its supply chain in line with the projected growth of the product.
Juniper previously reported that Crinone product revenues increased 19% year-over-year in the third quarter of 2017.
Crinone 8% (progesterone gel) is a bioadhesive progesterone vaginal gel indicated for progesterone supplementation of the luteal phase in women as part of an ART (assisted reproductive technology) procedure, among other indications depending upon the country.
Juniper Pharmaceuticals core businesses include its Crinone (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. The company is also leveraging its differentiated intravaginal ring technology, which offers the potential to address unmet needs in women's health.